Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant PK in Chinese participants with advanced breast cancer
NCT05732428Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoints: Single dose Maximum plasma concentration at Day 2, Single dose Area under the concentration-time curve over the dosing interval at Day 2 and 2 more. Started Feb 2023; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05732428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732428.